Lv21
130 积分 2026-01-06 加入
《危害药品目录》中国专家共识
1小时前
待确认
Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough
4个月前
已关闭
GLP-1RA–Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies
4个月前
已完结
Coming full circle: could glucagon-like peptide-1 receptor agonists confer a net perioperative benefit?
4个月前
已关闭
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
4个月前
已完结
Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial
4个月前
已完结
Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
4个月前
已完结
Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin
4个月前
已完结
Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation
4个月前
已完结
Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis
4个月前
已完结
皖公网安备34019202002308
